Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31283258 | 0.98 | ALDH1A1 (0.36) | ALDH1A1OPRM1NEK2CRBN | |
| SCHEMBL21201862 | 0.88 | SOS1 (0.37) | ALDH1A1CRBN | |
| SCHEMBL16189948 | 0.84 | — | — | |
| SCHEMBL7357702 | 0.80 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL7288250 | 0.80 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL4103157 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL22036847 | 0.77 | CHRM2 (0.38) | ALDH1A1NEK2 | |
| SCHEMBL6633187 | 0.77 | OPRM1 (0.32) | OPRM1NEK2 | |
| Ethylene SCHEMBL7382155 | 0.77 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL15478458 | 0.76 | NEK2 (0.33) | ALDH1A1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | claimed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | claimed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-109641886-B | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3448522-B1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IOMET PHARMA LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2018-10-25 | — | — | US | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017189386-A1 | NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE | IOMET PHARMA LTD. (GB) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRD3, BRDT | ALDH1A1 4523/4885OPRM1 4153/4885NEK2 423/4885 |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | ALDH1A1 4433/4885OPRM1 4246/4885NEK2 543/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 4433/4885OPRM1 4246/4885NEK2 543/4885 |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | ALDH1A1 2135/4885OPRM1 3459/4885NEK2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.